PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | |infections |
| Sentences | 173 |
| PubMedID- 25680398 | We believe that manuka honey may have a role to play in the management of cystic fibrosis patients with chronic respiratory infections, and in the future, we intend to investigate the activity of honey with a much larger range of bacteria and antibiotic combinations and to determine the susceptibilities of biofilms, as well as suspension cultures. |
| PubMedID- 22798960 | The β-hairpin mimetic pol7080 is currently in a phase i clinical trial in europe, and could represent an important drive in the treatment of chronic lung infections in patients with cystic fibrosis where p. aeruginosa plays a crucial role. |
| PubMedID- 24015228 | Given the increasing prevalence of multi-antibiotic resistant strains of p. aeruginosa bacteria, novel therapeutic approaches for the treatment of chronic infections in individuals with cystic fibrosis will be essential to ensure the continued health of these patients in the coming years. |
| PubMedID- 23844246 | B. cenocepacia is an environmental, opportunistic pathogen that causes serious infections in patients with cystic fibrosis and expresses high-level multidrug resistance 2. |
| PubMedID- 25453270 | Pneumonia, tuberculosis and infections occurring due to cystic fibrosis are in focus of this review. |
| PubMedID- 25653647 | Pseudomonas aeruginosa is the most common cause of chronic lung infections affecting individuals with cystic fibrosis (cf). |
| PubMedID- 23503622 | The non-motile forms are very difficult to eradicate and are often associated with the establishment of persistent infections, especially in patients with cystic fibrosis. |
| PubMedID- 25013584 | Burkholderia cepacia is another important pathogen causing pulmonary infections in people with cystic fibrosis (cf). |
| PubMedID- 21977035 | P. aeruginosa causes chronic respiratory infections in people with cystic fibrosis (cf) and acts as opportunistic pathogen causing bacteraemia, urinary tract infections, and hospital acquired pneumonia in patients with burns, urinary catheters, and those on invasive ventilation 1. |
| PubMedID- 21935381 | P. aeruginosa is often the cause of life-threatening infections in people with cystic fibrosis, burns victims and immuno-compromised individuals . |
| PubMedID- 24604671 | Background: viral respiratory tract infections in people with cystic fibrosis have a deteriorating effect on their lung function and disease progression. |
| PubMedID- 24995163 | Liposomal ciprofloxacin has been further developed by aradigm corporation for pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. |
| PubMedID- 22555873 | Pseudomonas aeruginosa is an opportunistic pathogen that causes chronic infections in the lungs of individuals with cystic fibrosis. |
| PubMedID- 24856524 | infections in patients with cystic fibrosis: diagnostic microbiology update. |
| PubMedID- 23166496 | It causes particularly difficult to treat infections in people with cystic fibrosis (cf), burn wounds, trauma, and compromised immune systems , . |
| PubMedID- 22973562 | Micronized gentamicin powders have been delivered by the pulmonary route for the treatment of infections associated with cystic fibrosis (goldman et al., 1990), but there are no reports of the use of micronized antibiotics for tb treatment. |
| PubMedID- 22321740 | Background: burkholderia cenocepacia is an opportunistic pathogen causing life-threatening infections in patients with cystic fibrosis. |
| PubMedID- 23773707 | Since this work, mlst has been applied in several studies of p. aeruginosa to better understand the epidemiology of infections in patients with cystic fibrosis and to study multiresistant clones. |
| PubMedID- 21511763 | P. aeruginosa infections associated with cystic fibrosis are resistant to current therapies, and molecules inhibiting toxin production or signals controlling their production should be able to reduce infection and aid in the clearance of this pathogen. |
| PubMedID- 26438797 | Pseudomonas aeruginosa infections persist in patients with cystic fibrosis (cf) and drive lung disease progression. |
| PubMedID- 21151973 | It is a cause of life-threatening lung infections in individuals with cystic fibrosis (cf), which are impossible to eradicate due to the biofilm lifestyle, adopted by this microorganism . |
| PubMedID- 24665407 | Mucociliary dysfunction, in addition to causing obstruction of airways, may also promote recurrent and persistent respiratory infections as evidenced in patients with cystic fibrosis, ciliary dyskinesia, and copd.73-76 mucin glycoproteins have been shown to interact with several respiratory pathogens including pseudomonas aeruginosa, staphylococcus aureus, heamophilus influenzae, streptococcus pneumonia, burkholderia cenocepacia, influenza virus, adenovirus, and coronavirus.77-83 the bound pathogens which are cleared under normal conditions may persist in the airway lumen when the mucociliary clearance is impaired, and initiate an inflammatory response which can damage the airway epithelium. |
| PubMedID- 23029239 | For example, high persistence mutants have been isolated from cystic fibrosis patients with lung infections and from patients with candidiasis . |
| PubMedID- 22629423 | The bcc, which is a complex composed of more than 10 burkholderia species, including b. cepacia, b. cenocepacia, and b. multivorans, is a group of nosocomial pathogens of increasing concern as these bacteria cause respiratory and systemic infections in patients with cystic fibrosis (cf) or chronic granulomatous disease, and in other immuno-compromised patients . |
| PubMedID- 25669133 | cystic fibrosis patients with p. aeruginosa infections have highly viscous sputum with edna concentrations of 3–14 mg/ml and pyocyanin concentrations up to 27 μg/ml (~130 μm)1819. recently, pyocyanin was shown to facilitate edna binding to p. aeruginosa cell surfaces to affect cellular aggregation20. |
| PubMedID- 21775220 | Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. |
| PubMedID- 21629778 | Studies of cough aerosols from pulmonary tuberculosis patients and cystic fibrosis patients with bacterial infections found that the concentration of infectious particles varied widely between patients , . |
| PubMedID- 21797692 | Evidence is accumulating that certain infections, for example, of medical devices, the cystic fibrosis lung, the oral cavity, the gi tract and wounds, are in fact polymicrobial, with more than one microbe involved. |
| PubMedID- 26253522 | Pseudomonas aeruginosa causes chronic lung infections in people with cystic fibrosis (cf) and acute opportunistic infections in people without cf. |
| PubMedID- 20948804 | It is also the leading bacterial cause of acute ventilator-associated pneumonia and chronic lung infections in patients with cystic fibrosis (cf). |
| PubMedID- 25850766 | Cepacia complex (bcc) which causes opportunistic infections in people with cystic fibrosis and immunocompromised patients. |
| PubMedID- 22589289 | It is also an important opportunistic human pathogen and major contributor to chronic lung infections in patients with cystic fibrosis (cf). |
| PubMedID- 26187366 | Burkholderia cenocepacia and other members of the burkholderia cepacia complex (bcc) are highly multidrug-resistant bacteria that cause severe pulmonary infections in patients with cystic fibrosis. |
| PubMedID- 21208930 | Functional quorum sensing systems are maintained during chronic burkholderia cepacia complex infections in patients with cystic fibrosis. |
| PubMedID- 24687506 | Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. |
| PubMedID- 21904046 | B. pseudomallei is closely related to b. mallei, the organism that causes glanders, and more distantly related to b. cenocepacia, an organism that causes acute infections in patients with cystic fibrosis. |
| PubMedID- 24010944 | S. aureus scvs are characterized by their slow growth rate and small colony size relative to the parent strain, and can cause persistent infections in the lungs of cystic fibrosis patients and infections of skin, bone and implanted devices 2. |
| PubMedID- 24565502 | Reports from the united states, france, and israel have shown that the m. abscessus group accounts for a major proportion of ntm infections in patients with cystic fibrosis; prevalence rates range from 16% to 48% (1–3). |
| PubMedID- 21343449 | The antimicrobial and hemolytic activities of a host defense peptide can be controlled by its modification as a propeptide of reduced net charge, which can then be processed by neutrophil elastase, a serine protease involved in chronic airway inflammation and infections associated with cystic fibrosis. |
| PubMedID- 23824677 | Background: vancomycin is the drug-of-choice for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infections in children with cystic fibrosis. |
| PubMedID- 20643851 | The burkholderia cepacia complex (bcc) is a group of genetically related environmental bacteria that can cause chronic opportunistic infections in patients with cystic fibrosis (cf) and other underlying diseases. |
| PubMedID- 23233287 | In humans, p. aeruginosa causes serious, and often chronic, infections in those with cystic fibrosis and in immunocompromised individuals, such as those with aids, patients undergoing chemotherapy and those with severe burns (lyczak et al. |
| PubMedID- 23235684 | Objectives: the objective of our review was to compare antibiotic treatment to no antibiotic treatment, or to compare different combinations of antibiotic treatment, for nontuberculous mycobacteria lung infections in people with cystic fibrosis. |
| PubMedID- 25267676 | Burkholderia cenocepacia is notorious for causing respiratory tract infections in people with cystic fibrosis. |
| PubMedID- 24260482 | Burkholderia cepacia complex (bcc) is an opportunistic bacterial pathogen that causes chronic infections in people with cystic fibrosis (cf). |
| PubMedID- 24671511 | Scientific reports suggest p. aeruginosa as the most important pathogen and causal agent of chronic pulmonary infections in patients with cystic fibrosis, which leads to gradual and eventually fatal decline in pulmonary function (govan and deretic 1996). |
| PubMedID- 26070573 | Aerosolized antibiotics have been tested as treatment for bacterial infections in patients with cystic fibrosis (cf), non-cf bronchiectasis (ncfb), and ventilator-associated pneumonia (vap). |
| PubMedID- 25741986 | Authors' conclusions: the current evidence is insufficient to recommend choosing antibiotics based on biofilm antimicrobial susceptibility testing rather than conventional antimicrobial susceptibility testing in the treatment of pseudomonas aeruginosa pulmonary infections in people with cystic fibrosis. |
| PubMedID- 24688762 | Spectrum of viral infections in patients with cystic fibrosis. |
| PubMedID- 22035265 | For example, there are reports of falsely negative results of classic bacterial cultures on saliva samples in microbiological diagnostics of respiratory infections in patients with cystic fibrosis 4. |